Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$28.83 USD
+0.06 (0.21%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $28.83 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DNTH 28.83 +0.06(0.21%)
Will DNTH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation
Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
Other News for DNTH
J&J submits FDA application for myasthenia gravis drug nipocalimab
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Nuvalent (NUVL) and Dianthus Therapeutics (DNTH)
Promising Clinical Developments Bolster Buy Rating for Dianthus Therapeutics
Navigating 4 Analyst Ratings For Dianthus Therapeutics
Commit To Buy Dianthus Therapeutics At $25, Earn 26.1% Annualized Using Options